Table 1 Clinicopathological characteristics of patients with GS, CIN-intestinal, and CIN-diffuse/mixed tumors.

From: Chromosomal copy number based stratification of gastric cancer has added prognostic value to Lauren’s histological classification

 

GS-intestinal

GS-diffuse

CIN-intestinal

CIN-diffuse

P value

(n = 24)

(n = 57)

(n = 142)

(n = 86)

Age

    

0.019

 Mean (range)

63.0 (42–83)

60.9 (33–80)

65.9 (21–84)

62.6 (31–84)

 

Sex

    

0.0023

 Male

9 (37.5%)

23 (40.4%)

91 (64.1%)

40 (46.5%)

 

 Female

15 (62.5%)

34 (59.6%)

51 (35.9%)

46 (53.5%)

 

Tumor localization

    

0.24

 Proximal

4 (16.7%)

3 (5.3%)

15 (10.6%)

8 (9.3%)

 

 Middle

8 (33.3%)

16 (28.1%)

36 (25.4%)

21 (24.4%)

 

 Distal

11 (45.8%)

29 (50.9%)

80 (56.3%)

41 (47.7%)

 

 >2/3 of stomach

1 (4.2%)

9 (15.8%)

11 (7.7%)

16 (18.6%)

 

pT stage

    

0.00050

 pT1

13 (54.2%)

17 (29.8%)

24 (16.9%)

5 (5.8%)

 

 pT2

1 (4.2%)

6 (10.5%)

20 (14.1%)

11 (12.8%)

 

 pT3

6 (25.0%)

19 (33.3%)

62 (43.7%)

31 (36.0%)

 

 pT4

4 (16.7%)

15 (26.3%)

36 (25.4%)

38 (44.2%)

 

 Missings

0 (0.0%)

0 (0.0%)

0 (0.0%)

1 (1.2%)

 

pN stage

    

0.0045

 pN0

14 (58.3%)

23 (40.4%)

44 (31.0%)

18 (20.9%)

 

 pN1

3 (12.5%)

7 (12.3%)

32 (22.5%)

16 (18.6%)

 

 pN2

2 (8.3%)

14 (24.6%)

39 (27.5%)

18 (20.9%)

 

 pN3

5 (20.8%)

13 (22.8%)

27 (19.0%)

34 (39.5%)

 

TNM (7th edition)

    

0.0010

 Stage I

13 (54.2%)

17 (29.8%)

33 (23.2%)

9 (10.5%)

 

 Stage II

4 (16.7%)

15 (26.3%)

39 (27.5%)

20 (23.3%)

 

 Stage III

6 (25.0%)

24 (42.1%)

67 (47.2%)

50 (58.1%)

 

 Stage IV

1 (4.2%)

1 (1.8%)

3 (2.1%)

7 (8.1%)

 

p53 IHC

    

0.00011

 Normal expression

8 (33.3%)

27 (47.4%)

25 (17.6%)

24 (27.6%)

 

 Aberrant expression

5 (20.8%)

7 (12.3%)

48 (33.8%)

29 (33.7%)

 

 Missings

11 (45.8%)

23 (40.4%)

69 (48.6%)

33 (38.4%)

 

CDH1 IHC

    

0.092

 Normal expression

11 (45.8%)

28 (49.1%)

71 (50.0%)

49 (57.0%)

 

 Aberrant expression

3 (12.5%)

7 (12.3%)

5 (3.5%)

9 (10.5%)

 

 Missings

10 (41.7%)

22 (38.6%)

66 (46.5%)

28 (32.6%)

 

Genome Instability Index

    

<0.0001

 GII-low

15 (62.5%)

45 (78.9%)

5 (3.5%)

8 (9.3%)

 

 GII-high

9 (37.5%)

12 (21.1%)

137 (96.5%)

78 (90.7%)

 
  1. Data are presented as number (percentage) of patients unless otherwise indicated.
  2. GS genomically stable, CIN chromosomal instable, IHC immunohistochemistry, GII Genome Instability Index.
Back to article page